Biophytis today announces that it has received approval from Brazil’s National Health Surveillance Agency (ANVISA) to begin the Phase 2 OBA clinical trial for obesity in Brazil and shares the outlook for its drug candidate BIO101 in obesity. The authorization, published in the Diário Oficial da União (Brazil’s Federal Official Gazette), represents a key regulatory…
Biophytis reports its financial results for the first half of 2025 and provides an update on its strategic outlook. Stanislas Veillet, Chief Executive Officer of Biophytis, stated: “The first half of 2025 marks a decisive milestone in the execution of our strategy. With the signing of a memorandum of understanding to create a joint venture…
Biophytis unveils Phase 3 Sarcopenia Trial Strategy with BIO101 in Europe and Asia Biophytis provides a detailed update on its clinical and regulatory plan for the Phase 3 SARA trial of BIO101, targeting age related sarcopenia. This trial is designed to be the first phase 3 ever conducted in sarcopenia, reflecting the medical need in…
Biophytis unveils Phase 2 Obesity Trial Strategy with BIO101 in Europe and Brazil Biophytis provides a detailed update on its clinical and regulatory plan for the Phase 2 OBA trial of BIO101, targeting muscle wasting associated with obesity. This new program underscores Biophytis’s ambition to broaden the potential of its lead candidate BIO101 into high-prevalence…
Obesity: Biophytis Charts Its Course Toward a Booming Market Biophytis is seizing a major opportunity in the expanding obesity market by addressing an unmet medical need: preserving muscle mass and function in patients losing weight while treated with GLP-1 receptor agonists. GLP-1 therapies such as semaglutide and tirzepatide have revolutionized obesity management by enabling significant…
Biophytis targets mobility restoration in patients with obesity Biophytis strentghens its position as one of the leading players in preserving muscle function in patients with obesity treated with GLP-1 therapies. While these treatments are revolutionizing obesity care by delivering significant weight loss, they also induce a concerning loss of muscle mass, which can compromise patients’…
Biophytis Confirms the Launch of the Phase 2 OBA Clinical Trial in Obesity Biophytis confirms the launch of the Phase 2 OBA clinical study in obesity, expected to begin as early as possible in 2025. Following the recent €2.6 million capital increase announced on March 26, 2025, and promising preclinical results presented at the 15th…
Biophytis unveils its outlook strategies for 2025 Biophytis today unveils its strategic outlook for the year 2025. Biophytis has improved its competitive positioning and fundamentals in recent months, paving the way for accelerated execution of its strategic roadmap: Launch of the OBA clinical development program for the treatment of obesity, Strategic licensing agreement signed with…
Biophytis announces the design of its phase 2 OBA clinical study in obesity Biophytis announces the design of its phase 2 OBA clinical study in obesity with BIO101 (20-hydroxyecdysone). BIO101 (20-hydroxyecdysone) will be evaluated in obese patients treated with GLP-1 RAs, together with hypocaloric dieting. The OBA phase 2 study will test the efficacy and…
Biophytis today the implementation of a dedicated strategy for partner search in obesity. Biophytis is continually working on the search for partners thanks to a sound strategy and action plan, with the Company being fully committed to drive groundbreaking scientific and technological advances that have the potential to transform the lives of obese patients worldwide.…
Biophytis announces new Scientific Advisory Board for its phase 2 OBA clinical study in obesity IND to be filed with the FDA in the coming weeks Biophytis announces the formation of a new Scientific Advisory Board to support the advancement of its phase 2 OBA clinical study in obesity. This Scientific Advisory Board will be…
Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone) Promising preclinical results obtained in obesity support the OBA Phase 2 clinical study expected to start mid-2024 Biophytis announces that it is launching a new clinical development program named OBA, with BIO101 (20- hydroxyecdysone) as a potential treatment for obesity in combination with…
Biophytis appoints Yann Meunier and Bernard Lévy to its Scientific Advisory Board Biophytis announced the appointment of Dr Yann Meunier and Professor Bernard Lévy to its Scientific Advisory Board. Yann Meunier is a US-based healthcare professional, currently Professor and Director of the International Institute of Medicine and Science, Inc (IIMS), where he leads the development…
Biophytis provides an update on its early access programs for Sarconeos (BIO101) in the treatment of severe forms of COVID-19 Biophytis announced that it has received a response from the French National Authority for Health (HAS) to its request for Early Access Authorization in France for patients suffering from severe forms of COVID-19 and provides…
Biophytis Strengthens its Management Team with the Appointment of its Chief Business Officer Biophytis announced the strengthening of its management team with the appointment of Edouard Bieth as Chief Business Officer and member of the Executive Committee. Stanislas Veillet, Chief Executive Officer of Biophytis, stated: “Over the past two years, Biophytis has made significant progress…
Biophytis announces next regulatory steps in Europe and the United States for its COVA project Biophytis announced that it has received feedback from the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) enabling it to plan the next regulatory steps for its COVA project dedicated to the development of Sarconeos (BIO101) for…
Biophytis strengthens its management team Appointment of Chiara Baccelli as Director of Pharmaceutical Operations and Quality Assurance Appointment of Nicolas Fellmann as Chief Financial Officer Fullscreen Mode
Biophytis to meet with FDA to advance Sarconeos (BIO101) development in Sarcopenia from Phase 2 to Phase 3 Following Phase2b/SARA-INT clinically meaningful results, Biophytis is starting first regulatory activities to advance from Phase 2 to Phase 3 development A Type B/End-of-Phase 2 meeting is planned with FDA (Food and Drug Administration) on January 24th, 2022,…
Biophytis announces US centers to restart recruitment for the COVA phase 2-3 study with Sarconeos (BIO101) in COVID-19 Biophytis announces that patient recruitment in the United States, paused in May while waiting for results of the Interim Analysis 2, has restarted. The Data Monitoring Committee (DMC) had recommended in September from the Interim Analysis 2…
Biophytis today announces the appointment of Rob van Maanen MD MBA as Chief Medical Officer, member of the Executive Committee.
Judgment rendered on July 16, 2021 in the proceedings between Biophytis and Negma Group Ltd by the Execution Judge from the Paris Court of Justice
Biophytis Reinforces Leadership Teams with Three Senior Appointments Fullscreen Mode
Upcoming Potential Value Generating Milestones. Read the Press Release
Biophytis has appointed Evelyne Nguyen as CFO and Strengthens Senior Management Team. Read the Press Release
